Updated iMMagine-1 data presented at ASH 2025 show that anito-cel delivers deep, durable responses in heavily pretreated multiple myeloma.
The Changing Landscape of Immunotherapy in Relapsed/Refractory Myeloma: Updates From ASH 2025
At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
2
Heart Failure Deaths Shift to Home, Hospice, but Racial Disparities Persist
3
ICYMI: Highlights From ESMO 2025
4
Obstructive Sleep Apnea Identified as Potential Risk Factor for Parkinson Disease
5
